0001438133-25-000157
SEC filingRevenue grew 8.5% YoY to $240.7M in Q2 2025, driven by US pump and supply volume growth, partially offset by litigation and IPR&D expenses.
For the three months ended June 30, 2025, Tandem Diabetes Care reported total sales of $240.7 million, an increase of 8.5% compared to $221.9 million in the same period of 2024. The growth was driven by higher pump and supply volumes in the United States, partially offset by a slight decline in international pump shipments. Gross profit rose to $125.9 million (52% gross margin) from $112.8 million (51% gross margin) in the prior year, with the margin improvement attributed to higher average selling prices, partially offset by less favorable product mix and non-manufacturing costs.
Operating expenses increased significantly to $177.7 million from $143.6 million, primarily due to a $20.0 million litigation and settlement expense related to a cross-license agreement with Roche. Selling, general and administrative expenses rose to $109.6 million from $94.2 million, driven by commercial investments in sales infrastructure, European direct operations, and efficiency initiatives. Research and development expenses decreased slightly to $48.1 million from $49.3 million, reflecting lower employee-related costs from restructuring. The company reported an operating loss of $51.8 million, compared to a loss of $30.8 million in the prior year. Net loss was $52.4 million versus $30.8 million.
In the United States, sales increased 8.6% to $170.2 million, with pump sales of $85.5 million and supply sales of $84.7 million. Pump shipments rose to approximately 21,000 units from 20,000 in Q2 2024. Outside the United States, sales grew 8.1% to $70.5 million, driven by supply volume growth and favorable foreign exchange, though pump shipments declined to approximately 9,000 from nearly 10,000. The mix shift toward supplies, which carry lower gross margins than pumps, partially offset the benefit of higher average selling prices.
The MD&A does not provide explicit forward guidance. Management highlights several strategic priorities: expanding the Tandem Mobi launch internationally following CE Mark approval in May 2025, implementing a multi-channel managed care strategy (including pharmacy channel for Tandem Mobi and future supply sales), and advancing the product pipeline (including Sigi patch pump, tubeless infusion option, and fully closed-loop technology). The company expects continued seasonality, with higher pump shipments in the second half of the year due to US insurance deductible resets. Key risks include regulatory delays, competitive launches, and macroeconomic uncertainties such as inflation and tariff impacts.
As of June 30, 2025, Tandem held $64.1M in cash and cash equivalents and $251.2M in short-term investments (primarily U.S. government and corporate debt securities), totaling $315.3M in liquid assets. Total assets were $875.7M, while total liabilities were $742.5M, resulting in stockholders' equity of $133.3M. Inventories stood at $142.6M, and deferred revenue (current and long-term) was $20.1M. The company had $309.1M in net convertible senior notes due 2029 (net of unamortized issuance costs) and no current portion of debt following the maturity of the 2025 notes in May 2025.
Tandem's operating lease commitments totaled $182.6M undiscounted, with $19.9M due within one year and $119.8M classified as long-term. Additionally, the company has a $36.0M settlement payable to Roche over four years (present value $31.6M, with $8.0M paid in Q2 2025 and $4.4M imputed interest). An acquisition-related payable of $35.2M (CHF 28M) is due in October 2025 for AMF Medical. The company also has a $4.9M promissory note payable (assumed in Capillary Biomedical acquisition) and a $4.9M standby letter of credit.
No share repurchases occurred in the first half of 2025 (vs. $30.0M in H1 2024). The company repaid $40.8M of its 2025 convertible notes at maturity using cash. Capital expenditures were $9.2M (1.9% of sales). No dividends are paid. The company used $43.5M for the AMF Medical acquisition (IPR&D). Stock-based compensation was $51.1M.
Tandem operates as a single reportable segment: Insulin Pumps and Supplies. For the six months ended June 30, 2025, total sales were $475.1M, with 67.5% in the U.S. ($320.8M) and 32.5% outside the U.S. ($154.3M). Product breakdown: pump sales $214.0M, supplies and other $261.1M. Distributor sales accounted for 61% of U.S. sales and nearly all international sales.
For the six months ended June 30, 2025, Tandem Diabetes Care reported a net loss of $183.0 million, while net cash used in operating activities was $27.8 million. The significant gap between net loss and operating cash flow is primarily due to large non-cash charges: stock-based compensation ($51.1M), depreciation and amortization ($8.7M), acquired in-process R&D expenses ($75.2M), and operating lease impairment ($6.7M). These adjustments more than offset the net loss, resulting in operating cash burn that was substantially lower than the net loss.
Capital expenditures (capex) were $9.2 million, representing a modest 33% of operating cash outflow, indicating low capital intensity. Free cash flow (not explicitly stated) would be approximately -$37.0 million (operating cash flow minus capex).
Working capital changes consumed $7.5 million of cash, driven by a $13.5 million increase in accounts receivable (likely from higher sales) and a $12.6 million decrease in employee-related liabilities, partially offset by a $12.1 million reduction in inventories. No share repurchases or dividends were paid; financing activities were dominated by $40.8 million in principal payments on convertible notes due 2025.
Overall, cash flow quality is weak due to persistent operating losses, though non-cash charges provide a buffer. The company remains reliant on prior-period financing activities (debt issuance) to fund operations and capex.